Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists

Hesketh, Paul J.; Belle, Simon Van; Aapro, Matti; Tattersall, F.D.; Naylor, R.J.; Hargreaves, Richard; Carides, Alexandra D.; Evans, Judith K.; Horgan, Kevin J.

doi:10.1016/s0959-8049(02)00674-3

Cited by 220 publications

(158 citation statements)

References 31 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Additionally, it is very difficult to assess the properties of the toxin detection system using CFA testing because the conditioning protocol involves a delay in testing that is not conducive to a detailed temporal analysis of malaise. For example, it is clear from research on emesis that an analysis of the acute and delayed phases of toxin detection is critical, but this type of investigation is not possible using CFA or learned flavour aversion testing (Hesketh et al, 2003). Although CFA and learned flavour aversion appear to measure the malaise producing potential of a stimulus, this is probably not always true.…”

Section: Conditioned Flavour Avoidance (Cfa)-manymentioning

confidence: 99%

“…Furthermore, there appears to be a close association between the neuropharmacology of toxicosisinduced pica and emesis. Like emesis in cancer patients receiving chemotherapy (Tsukada et al, 2001;Hesketh et al, 2003;de Wit et al, 2004), cisplatin-induced pica in the rat can be characterized into acute and delayed phases that are most sensitive to 5-HT3 and NK1 receptor antagonists, respectively (Saeki et al, 2001;Rudd et al, 2002). However, the relation between emesis and pica is not always so clear.…”

Section: Kaolin Ingestion (Pica)-mentioning

confidence: 99%

See 1 more Smart Citation

Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases

Andrews

Horn

2006

Autonomic Neuroscience

214

200

View full text Add to dashboard Cite

Nausea and vomiting are amongst the most common symptoms encountered in medicine as either symptoms of diseases or side effects of treatments. In a more biological setting they are also important components of an organism's defences against ingested toxins. Identification of treatments for nausea and vomiting and reduction of emetic liability of new therapies has largely relied on the use of animal models, and although such models have proven invaluable in identification of the anti-emetic effects of both 5-hydroxytryptamine3 and neurokinin1 receptor antagonists selection of appropriate models is still a matter of debate. The present paper focuses on a number of controversial issues and gaps in our knowledge in the study of the physiology of nausea and vomiting including: The choice of species for the study of emesis and the underlying behavioural (e.g. neophobia), anatomical (e.g. elongated, narrow abdominal oesophagus with reduced ability to shorten) and physiological (e.g. brainstem circuitry) mechanisms that explain the lack of a vomiting reflex in certain species (e.g. rats); The choice of response to measure (emesis[retching and vomiting], conditioned flavour avoidance or aversion, ingestion of clay [pica], plasma hormone levels[e.g. vasopressin], gastric dysrhythmias) and the relationship of these responses to those observed in humans and especially to the sensation of nausea; The stimulus coding of nausea and emesis by abdominal visceral afferents and especially the vagus-how do the afferents encode information for normal postprandial sensations, nausea and finally vomiting?; Understanding the central processing of signals for nausea and vomiting is particularly problematic in the light of observations that vomiting is more readily amenable to pharmacological treatment than is nausea, despite the assumption that nausea represents "low" intensity activation of pathways that can evoke vomiting when stimulated more intensely.

show abstract

Section: Conditioned Flavour Avoidance (Cfa)-manymentioning

confidence: 99%

Section: Kaolin Ingestion (Pica)-mentioning

confidence: 99%

Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases

Andrews

Horn

2006

Autonomic Neuroscience

214

200

View full text Add to dashboard Cite

show abstract

“…This definition is rather relative since evidence emerged, demonstrating that the duration of acute emesis is beyond the first 24 hours, as delayed emesis probably already starts after 8-12 hours. [7] Other important categories include anticipatory, breakthrough, and refractory emesis. Anticipatory vomiting occurs before, during, or after the initiation of therapy and is a conditioned response linked to various factors associated with previous chemotherapy.…”

Section: Types Of Cinvmentioning

confidence: 99%

“…Before that period the only available drugs for prevention or treatment of CINV were neuroleptics and steroids. [7] Setrons or 5HT3 receptor antagonists Serotonin is released by enteroendocrine cells in the gastrointestinal tract following administration of cytotoxics. Binding to the 5HT3 receptors (mainly located in the abdominal vagal afferents) kicks off the emetic reflex.…”

Section: Available Drugsmentioning

confidence: 99%

Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Ryckeghem

2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in antiemetic therapy has progressed gradually since the early eighties, and the development of antiemetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines, and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids, and NK-1 receptor antagonists are the cornerstones of antiemetic therapy. Corticosteroids are one of the oldest agents in the prevention of CINV. They are highly effective, increase the effect of other antiemetic agents, and are cost-effective. The latest developed 5HT3 receptor antagonist palonosetron led to an update of the guidelines of CINV. Other types include benzodiazepines, cannabinoids, and olanzapine. Various factors contribute to the overall risk of developing CINV, such as patient characteristics, emetogenic potency of the chemotherapeutic agents, and correct prevention of CINV. Current guidelines determine which is the right preventive regimen for each cancer patient at risk for experiencing CINV. Adherence to these guidelines and implementation in daily practice seem to be below the optimal level. In Belgium, authorities use the guidelines as a base for reimbursement and this has increased the level of implementation.

show abstract

“…항암제에 의한 구토는 CTZ, 위장관, 구토 중추에 위치한 신경전달 물질 수용체를 자극시켜서 일어나며, 세로토닌(serotonin), 도 파민(dopamine), P 물질(substance P), 히스타민(histamine), 아세틸콜린 (acetylcholine), 아편제(opiates) 등이 관여되어 있다고 알려져 있다 [2]. 항구토제는 이러한 신경전달 물질을 억제하는 것으로 세로토 닌 수용체 억제제로는 dolasetron (Anzemet), granisetron (Kytril), ondanseteron (Zofran), tropisetron (Navoban), palonosetron (Aloxi), mirtazapine (Remeron) 등이 있으며, 도파민 억제제로는 domperidone, droperidol, metoclopramide, alizapride, prochlorperazine 등이 있 으며, NK1 수용체 억제제는 aprepitant (Emend), casopitant가 있으 며, 항히스타민제제로 cyclizine, diphenhydramine, dimenhydrinate, meclozine, promethazine, hydroxyzine이 있다.…”

unclassified

Prophylactic antiemetics therapy against gynecologic cancer chemotherapy

Lee

Kwon

2011

Korean J Obstet Gynecol

View full text Add to dashboard Cite

Nausea and vomiting associated with gynecologic cancer chemotherapy are experienced by most of patients receiving chemotherapy. Assessment of vomiting risk by chemotherapy and risk factor are mandatory for rescue of chemotherapy induced nausea and vomiting (CINV). Piled-up evidence based medicine result in prophylactic antiemetics guideline from American Society of Clinical Oncology, Multinational Association for Supportive Care in Cancer, and National Comprehensive Cancer Network. Combination of serotonin receptor antagonist, dexamethason, and with/without NK1 antagonist is the best prophylaxis in patients receiving highly and moderate emetogenic chemotherapy. Other new regimens (palonosetron, transdermal granisetron) are introduced to relieve the active symptom of delayed CINV. Comprehensive understading of pathophysiology of CINV and tailored therapy for the patients are vital in prophylactic antiemetics therapy against gynecologic cancer chemotherapy.Keywords: Nausea, Vomiting, Antiemetics, Guideline

show abstract

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists

Cited by 220 publications

References 31 publications

Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases

Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases

Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Prophylactic antiemetics therapy against gynecologic cancer chemotherapy

Contact Info

Product

Resources

About